Food, drugs, devices › Hikma Pharmaceuticals USA Inc.

Drug recall: Lorazepam Injection, USP, 2mg/mL, 1 mL vial (NDC 0641-6044-01), packaged in 25 x 1 mL Vials per carton (NDC 0641-6044-25

FDA enforcement event 92320 · Class II · initiated 11 May 2023 · status Terminated · terminated 12 Dec 2023

DrugVoluntary: Firm initiated1 product recordCherry Hill, NJ

FDA enforcement event 92320 is a drug recall by Hikma Pharmaceuticals USA Inc. of Cherry Hill, NJ, initiated 11 May 2023 and classified Class II, with 1 product record.

FDA defines Class II as a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote. 59% of the 281 drug enforcement events initiated in 2023 carry the same class.

Status: Terminated, terminated 12 Dec 2023. Initiation: voluntary: firm initiated. Hikma Pharmaceuticals USA Inc. has 15 enforcement events on this register, with a median of 1 product record per event.

Recall classification reflects the relative degree of health hazard. Text in quotation marks is FDA's. openFDA export dated 28 Sep 2026.

Recalling firm

Hikma Pharmaceuticals USA Inc., Cherry Hill, NJ.

Reason for recall

"Failed Impurities/Degradation Specifications: Out-of-specification results for total related compounds observed during retain steting due to the elevated Related Compound-C."

Distribution

"Nationwide in the USA and Puerto Rico"

Product records

Recall number	Product	Quantity	Class	Status	Report date
D-0574-2023	Lorazepam Injection, USP, 2mg/mL, 1 mL vial (NDC 0641-6044-01), packaged in 25 x 1 mL Vials per carton (NDC 0641-6044-25), Rx only, Manufactured by West-Ward, Eatontown, NJ 07724.	1,352,475 vials	Class II	Terminated	24 May 2023

Context

59%of 2023 drug events are Class II281 events that year

1product record in this eventfirm median: 1

15events on this register for the firm

Other enforcement events for Hikma Pharmaceuticals USA Inc.

Initiated	Product (first record)	Type	Class	Records
24 Aug 2026	Ramipril Capsules USP, 10 mg, packaged in a) 100 Capsules (NDC 76282-673-01) and b) 500 Capsules (NDC 76282-673-05) bott	Drug	Class II	1
7 Apr 2026	Alendronate Sodium Oral Solution, 70 mg/75 mL, 75 mL, Rx only, 4 x 75 mL Single Dose Bottles, Distr. by: Hikma Pharmaceu	Drug	Class II	1
22 Jul 2025	Lorazepam Injection, USP, 2 mg/mL, 25 x 1mL vials/carton, Rx Only, Manufactured by: Hikma Berkeley Heights, NJ 07922, ND	Drug	Class II	1
8 Jul 2024	Acetaminophen Injection, 1,000 mg per 100 mL (10 mg/mL), 100 mL Single Dose bags, For Intravenous Use Only, Rx Only, Man	Drug	Class I	1
12 Mar 2024	Infumorph (Preservative-free Morphine Sulfate Sterile Solution), 20 mL ampul, Rx only, Manufactured by Hikma Berkeley He	Drug	Class II	1
16 Dec 2022	Ganciclovir for Injection, USP, 500mg per vial, packaged in a 10-count carton, Rx Only, Mfd. by: THYMOORGAN PHARMAZIE Gm	Drug	Class II	1
11 Jul 2022	Lorazepam Injection, USP, 2mg/mL, 1 mL vial, 25 vials per carton, RX Only, Manufactured by West-Ward Eatontown, NJ 07724	Drug	Class II	4
5 Aug 2021	Bleomycin for Injection, USP, packaged in 15 units per single dose vial, Rx only, Manufactured by Thymoorgan Pharmazie G	Drug	Class III	1
7 Dec 2020	Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/ml, 2mL Single Dose Vial, Rx Only, Mfd. by. West-ward Eatontown, NJ 0	Drug	Class II	1
3 Nov 2020	Sodium Chloride Injection, USP, 0.9%, 0.308 mOsmol/mL, 2mL Single Dose Vial, Preservative Free, For use as a sterile dil	Drug	Class II	1

All 15 events for Hikma Pharmaceuticals USA Inc.

Questions and answers

Why was this drug recalled?

FDA's record gives the reason for recall as: "Failed Impurities/Degradation Specifications: Out-of-specification results for total related compounds observed during retain steting due to the elevated Related Compound-C."

What does Class II mean?

FDA classifies recalls by relative degree of health hazard. Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote.

Where was the product distributed?

FDA's distribution pattern field reads: "Nationwide in the USA and Puerto Rico"

Is the recall still ongoing?

FDA lists the status as Terminated; the termination date is 12 Dec 2023. "Terminated" means FDA has determined that all reasonable efforts to remove or correct the product have been made.

Where does this data come from?

openFDA enforcement reports (food, drug and device), CC0, export dated 28 Sep 2026. Text in quotation marks is FDA's. The FDA enforcement report linked above is authoritative.

Provenance

Source: openFDA drug enforcement reports (CC0), export dated 28 Sep 2026; records grouped by FDA event number. The class shown for the event is the most severe class among its records. Errors in processing are corrected at the next build; see corrections.